Fact Check: Did Bharat Biotech’s CEO took the first dose of vaccine for COVID-19 “COVAXIN”
The Indian Council of Medical Research (ICMR) has kept in touch with Bharat Biotech India Ltd (BBIL) to step up the clinical preliminaries for their mutually created COVID-19 antibody (BBV152 COVID immunization) or ‘Covaxin’. In the perspective on this news, a photo is generally flowing via web-based networking media with the case that the primary portion of the antibody was controlled on the “VP of BBIL Dr VK Srinivas”.
The photograph is massively viral on Twitter and Facebook.
It is also being circulated on whatsapp
FACT-CHECK:
1. Bharat Biotech denies that the image represents clinal trials of BBV152
In an email response to Alt News, BBIL wrote, “Certain images and messages being circulated on WhatsApp and other social media platforms have NOT been disseminated by Bharat Biotech. The image being circulated is a routine procedural blood draw for testing all production staff. ”
BBV152 cannot be applied intravenously
BBV152 was enlisted for clinical preliminaries with ICMR’s Clinical Trials Registry. According to the enlistment report, the course of organization of the antibody is an intramuscular infusion.
Intra-solid immunizations are not given in the elbow pit district (cubital fossa) because of an absence of muscles here. The cubital fossa is utilized to get to shallow nerves, conduits and veins for intravenous organization. Besides, as found in the image, the individual is wearing a tourniquet elastic band on his arm. The band is utilized to squeeze a patient’s arm to draw blood. This is a pressure strategy, profoundly probably not going to be utilized while overseeing an antibody. The band is utilized to pool blood or collect blood to draw it intravenously, and this pooling of blood isn’t required for intramuscular immunization organizations.
